Status:
NOT_YET_RECRUITING
Anti-CD 19 CAR-T Cell Therapy in Patients with ANCA Vasculitis
Lead Sponsor:
David Simon
Collaborating Sponsors:
Kyverna Therapeutics
Conditions:
ANCA-IgG-positive ANCA Associated Vasculitis
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
PHASE2
Brief Summary
The goal of this phase I/II clinical trial is to investigate anti-CD 19 chimeric antigen receptor T cell (CAR-T cell) therapy in patients with antineutrophil cytoplasmic antibodies (ANCA) immunoglobul...
Detailed Description
This study aims to investigate the use of KYV101 (a fully human anti-CD19 CAR T cell therapy) in ANCA-IgG-positive AAV patients who are refractory to previous treatments. This study is designed to det...
Eligibility Criteria
Inclusion
- Understand and voluntarily sign an informed consent form
- Male or female, age ≥ 18 and ≤ 75 years at ti me of consent
- Able to adhere to the study visits and protocol
- Fulfilment of
- EITHER both of the following
- 2022 ACR-EULAR classification criteria for granulomatosis with polyangiitis (GPA)
- detectable anti-PR3 antibodies (≥ 20 AU/ml in CLIA) at screening
- OR both of the following
- 2022 ACR/EULAR classification criteria for microscopic polyangiitis (MPA)
- detectable anti-MPO antibodies (≥ 10 AU/ml in CLIA) at screening
- Active disease, defined as Clinical activity (BVAS ≥ 3) at screening
- Insufficient response or intolerance/contraindication to glucocorticoids and to at least one of the following treatments: rituximab, mycophenolate mofetil, azathioprine, methotrexate, cyclophosphamide, avacopan. Insufficient response is defined as having disease activity based on the definition explained in the previous bullet point
- Male subjects unless surgically sterile, must agree to use two acceptable methods for contraception (e.g. spermicide and condom) during the trial and refrain from fathering a child starting from the time of signing the Informed Consent Form (ICF) until 12 months after dosing of the IMP
- Females of childbearing potential (FCBP) must have a negative urine pregnancy test at screening and must agree to use a highly effective contraceptive method (Pearl index less than 1) starting from the time of signing the ICF and for 12 months after dosing of the IMP
- Updated vaccination record according to the STIKO recommendations for immuno-compromised patients
Exclusion
- ANC less than 500/µl, ALC less than 100/µl or hemoglobin less than 8g/dl, absolute CD3+T cell count less than 100/µl at screening
- Severely impaired renal (eGFR ≤ 30 ml/min/m2), liver (Child Pugh C), or heart or pulmonary (NYHA IV, blood oxygenation less than 92%) function
- Clinically relevant rapidly progressive glomerulonephritis or pulmonary alveolar hemorrhage
- Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
- Prior treatment with anti-CD19 antibody therapy, adoptive T cell therapy or any prior gene therapy product (e.g. CAR T cell therapy)
- History of bone marrow/ hematopoietic stem cell or solid organ transplantation
- Any concomitant severe active infection, e.g. HIV, hepatitis B or C, SARS-CoV-2 (COVID-19), or active tuberculosis as defined by a positive Quantiferon TB-test. If presence of latent tuberculosis is established then treatment according to local guide-lines must have been initiated prior to enrollment
- Pregnant or lactating females
- Females who are intending to conceive during the study
- Known hypersensitivity to any drug components
- Malignancy in the last 5 years before screening (except adequately treated basal or squamous cell skin cancer)
- Requirement for immunization with live vaccine during the study period or within 14 days preceding leukapheresis,
- Subjects who are younger than 18 years or are incapable to understand the aim, importance and consequences of the study and to give legal informed consent (accord-ing to § 40 Abs. 4 and § 41 Abs. 2 and Abs. 3 AMG),
- Have a history of alcohol or substance abuse within the preceding 6 months that, in the opinion of the Investigator, may increase the risks associated with study participa-tion or study agent administration, or may interfere with interpretation of results,
- Subjects who possibly are dependent on the Sponsor, the Principal Investigator or Investigator (e.g. family members).
- Subjects who are institutionalized by order of court or public authority,
- Subjects participating in another clinical trial with an investigational medicinal product or medical device (3 months before this trial).
Key Trial Info
Start Date :
January 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2027
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT06590545
Start Date
January 1 2025
End Date
July 1 2027
Last Update
September 19 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.